US2003187187A1PendingUtilityA1
Polypeptide with appetite regulating activity
Priority: Mar 26, 1997Filed: Aug 26, 2002Published: Oct 2, 2003
Est. expiryMar 26, 2017(expired)· nominal 20-yr term from priority
A01K 2217/05A61K 38/00C07K 14/475
41
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to a polypeptide with appetite regulating function/activity, a nucleic acid construct encoding the polypeptide and a method of producing the polypeptide. The invention further relates to recombinant vectors comprising the nucleic acid construct encoding the polypeptide, recombinant host cells comprising the nucleic acid construct or the recombinant vector.
Claims
exact text as granted — not AI-modified1 . An isolated polypeptide comprising the sequence SEQ ID No. 1:
Gln-Glu-Asp-Ala-Glu-Leu-Gln-Pro-Arg-Ala-Leu-Asp-
Ile-Tyr-Ser-Ala-Val-Asp-Asp-Ala-Ser-His-Glu-Lys-
Glu-Leu- Pro-Arg-Arg-Gln-Leu-Arg-Ala-Pro-Gly-Ala-
Val-Leu-Gln -Ile-Glu-Ala-Leu-Gln-Glu-Val-Leu-Lys-
Lys-Leu-Lys-Ser- Lys-Arg -Ile-Pro-Ile-Tyr-Glu-Lys-
Lys-Tyr-Gly-Gln-Val-Pro-Met- Cys -Asp-Ala-Gly-Glu-
Gln- Cys -Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-
Leu- Cys -Asp- Cys -Pro-Arg-Gly-Thr-Ser- Cys -Asn-Ser-
Phe-Leu-Leu-Lys- Cys -Leu
in which the cysteine residues are linked by disulphide bonds in the configuration I-III, II-V and IV-VI when the cysteines are numbered from the N-terminal end.
2 . An isolated polypeptide comprising the sequence SEQ ID No. 2:
Gln-Glu-Asp-Ala-Glu-Leu-Gln-Pro-Arg-Ala-Leu-Asp-
Ile-Tyr-Ser-Ala-Val-Asp-Asp-Ala-Ser-His-Glu-Lys-
Glu-Leu-Ile-Glu-Ala-Leu-Gln-Glu-Val-Leu-Lys-Lys-
Leu-Lys-Ser- Lys-Arg -Ile-Pro-Ile-Tyr-Glu-Lys-Lys-
Tyr-Gly-Gln-Val-Pro-Met- Cys -Asp-Ala-Gly-Glu-Gln-
Cys-Ala-Val-Arg-Lys-Gly-Ala-Arg-IIe-Gly-Lys-Leu-
Cys -Asp- Cys -Pro-Arg-Gly-Thr-Ser- Cys -Asn-Ser-Phe-
Leu-Leu-Lys- Cys -Leu
in which the cysteine residues are linked by disulphide bonds in the configuration I-III, II-V and IV-VI when the cysteines are numbered from the n-terminal end:
3 . An isolated polypeptide comprising the sequence SEQ ID No. 3:
Gln-Glu-Asp-Ala-Glu-Leu-Gln-Pro-Arg-Ala-Leu-Asp-
Ile-Tyr-Ser-Ala-Val-Asp-Asp-Ala-Ser-His-Glu-Lys-
Glu-Leu-Ile-Glu-Ala-Leu-Gln-Glu-Val-Leu-Lys-Lys-
Leu-Lys-Ser- Lys-Arg -Val-Pro-Ile-Tyr-Glu-Lys-Lys-
Tyr-Gly-Gln-Val-Pro-Met- Cys -Asp-Ala-Cly-Glu-Gln-
Cys -Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-
Cys -Asp- Cys -Pro-Arg-Gly-Thr-Ser- Cys -Asn-Ser-Phe-
Leu-Leu-Lys- Cys -Leu
in which the cysteine residues are linked by disulphide bonds in the configuration I-III, II-V and IV-VI when the cysteines are numbered from the N-terminal end.
4 . An isolated polypeptide comprising the sequence SEQ ID No. 4:
Ile-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-
Met- Cys -Asp-Ala-Gly-Glu-Gln- Cys -Ala-Val-Arg-Lys-
Gly-Ala-Arg-Ile-Gly-Lys-Leu- Cys -Asp- Cys -Pro-Arg-
Gly-Thr-Ser- Cys -Asn-Ser-Phe-Leu-Leu-Lys- Cys -Leu
in which the cysteine residues are linked by disulphide bonds in the configuration I-III, II-V and IV-VI when the cysteines are numbered from the N-terminal end.
5 . An isolated polypeptide comprising the sequence SEQ ID No. 5:
Val-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-Pro-
Met- Cys -Asp-Ala-Gly-Glu-Gln- Cys -Ala-Val-Arg-Lys-
Gly-Ala-Arg-Ile-Gly-Lys-Leu- Cys -Asp- Cys -Pro-Arg-
Gly-Thr-Ser- Cys -Asn-Ser-Phe-Leu-Leu-Lys- Cys -Leu
6 . An isolated polypeptide comprising the sequence SEQ ID No. 6:
Arg-Ile-Pro-Ile-Tyr-Glu-Lys-Lys-Tyr-Gly-Gln-Val-
Pro-Met- Cys -Asp-Ala-Gly-Glu-Gln- Cys -Ala-Val-Arg-
Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu- Cys -Asp- Cys -Pro-
Arg-Gly-Thr-Ser- Cys -Asn-Ser-Phe-Leu-Leu-Lys- Cys -
Leu
7 . An isolated polypeptide comprising the sequence SEQ ID No. 7:
Lys-Tyr-Gly-Gln-Val-Pro-Met- Cys -Asp-Ala-Gly-Glu-
Gln-Cys-Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-
Leu- Cys -Asp- Cys -Pro-Arg-Gly-Thr-Ser- Cys -Asn-Ser-
Phe-Leu-Leu-Lys- Cys -Leu
8 . An isolated polypeptide comprising the sequence SEQ ID No. 8:
Tyr-Gly-Gln-Val-Pro-Met- Cys -Asp-Ala-Gly-Glu-Gln-
Cys -Ala-Val-Arg-Lys-Gly-Ala-Arg-Ile-Gly-Lys-Leu-
Cys -Asp- Cys -Pro-Arg-Gly-Thr-Ser- Cys -Asn-Ser-Phe-
Leu-Leu-Lys- Cys -Leu
9 . An isolated polypeptide comprising the sequence SEQ ID No. 9:
Cys -Asp-Ala-Gly-Glu-Gln- Cys -Ala-Val-Arg-Lys-Gly-
Ala-Arg-Ile-Gly-Lys-Leu- Cys -Asp- Cys -Pro-Arg-Gly-
Thr-Ser- Cys -Asn-Ser-Phe-Leu-Leu-Lys- Cys -Leu
10 . An isolated polypeptide according to any one of the claims 5 to 9 in which the cysteine residues are linked by disulphide bonds in the configuration I-III, II-V and IV-VI when the cysteines are numbered from the N-terminal end.
11 . A nucleic acid construct comprising a nucleotide sequence encoding a CART polypeptide or a fragment or variant thereof with appetite regulating activity/function.
12 . A nucleic acid construct according to claim 11 comprising a nucleotide sequence encoding a polypeptide with a sequence selected from the sequences SEQ ID Nos. 1 to 9.
13 . A nucleic acid construct according to claim 12 comprising a nucleotide sequence encoding a polypeptide with a sequence selected from the sequences SEQ ID Nos. 1 to 9 in which the cysteine residues are linked by disulphide bonds in the configuration I-III, II-V and IV-VI when the cysteines are numbered from the N-terminal end.
14 . A recombinant vector comprising the nucleic acid construct according to any one of the claims 11 to 13 .
15 . A recombinant host cell comprising the nucleic acid construct according to any one of the claims 11 to 13 or the vector according to claim 14 .
16 . The cell according to claim 15 , which is of mammalian, insect, plant, microbial, bacterial, or fungal origin.
17 . A transgenic animal containing and expressing the nucleic acid construct according to any one of the claims 11 to 13 .
18 . A transgenic plant containing and expressing the nucleic acid construct according to any one of the claims 11 to 13 .
19 . A method of producing a CART polypeptide or a fragment or variant thereof with appetite regulating activity/function, which method comprises cultivating a cell according to claim 15 or 16 in a suitable culture medium under conditions permitting expression of the nucleic acid construct and recovering the resulting polypeptide from the culture medium/cell.
20 . A method of producing a CART polypeptide or a fragment or variant thereof with appetite regulating activity/function, which method comprises recovering the polypeptide produced by the transgenic animal according to claim 17 .
21 . A method of producing a CART polypeptide or a fragment or variant thereof with appetite regulating activity/function, which method comprises growing a cell of a transgenic plant according to claim 18 , and recovering the polypeptide from the resulting plant.
22 . An antibody capable of specifically binding to a CART polypeptide or a fragment or variant thereof with appetite regulating activity/function.
23 . An antibody capable of specifically binding to a polypeptide with a sequence selected from the sequences SEQ ID Nos. 1 to 9.
24 . An antibody capable of specifically binding to a polypeptide with a sequence selected from the sequences SEQ ID Nos. 1 to 9 in which the cysteine residues are linked by disulphide bonds in the configuration I-III, II-V and IV-VI when the cysteines are numbered from the N-terminal end.
25 . An antibody according to any one of the claims 22 to 24 which is a monoclonal antibody.
26 . A hybridoma which produces a monoclonal antibody according to claim 25 .
27 . An appetite regulating composition comprising a CART polypeptide or a fragment or variant thereof and a pharmaceutical acceptable carrier.
28 . An appetite regulating composition according to claim 27 comprising a polypeptide with a sequence selected from the sequences SEQ ID Nos. 1 to 9 and a pharmaceutical acceptable carrier.
29 . An appetite regulating composition according to claim 28 comprising a polypeptide with a sequence selected from the sequences SEQ ID Nos. 1 to 9 in which the cysteine residues are linked by disulphide bonds in the configuration I-III, II-V and IV-VI when the cysteines are numbered from the N-terminal end and a pharmaceutical acceptable carrier.
30 . Use of a CART polypeptide or a fragment or variant thereof for the preparation of a medicament for the regulation of appetite.
31 . Use of a polypeptide with a sequence selected from the sequences SEQ ID Nos. 1 to 9 for the preparation of a medicament for the regulation of appetite.
32 . Use of a polypeptide with a sequence selected from the sequences SEQ ID Nos. 1 to 9 in which the cysteine residues are linked by disulphide bonds in the configuration I-III, II-V and IV-VI when the cysteines are numbered from the N-terminal end for the preparation of a medicament for the regulation of appetite.
33 . Use of a CART polypeptide or a fragment or variant thereof for the preparation of a medicament for the treatment of obesity.
34 . Use of a polypeptide with a sequence selected from the sequences SEQ ID Nos. 1 to 9 for the preparation of a medicament for the treatment of obesity.
35 . Use of a polypeptide with a sequence selected from the sequences SEQ ID Nos. 1 to 9 in which the cysteine residues are linked by disulphide bonds in the configuration I-III, II-V and IV-VI when the cysteines are numbered from the N-terminal end for the preparation of a medicament for the treatment of obesity.
36 . A method for the regulation of appetite comprising administering to an subject in need thereof an effective amount of an isolated CART polypeptide or a fragment or variant thereof.
37 . A method for the regulation of appetite comprising administering to an subject in need thereof an effective amount of a polypeptide with a sequence selected from the sequences SEQ ID Nos. 1 to 9.
38 . A method for the regulation of appetite comprising administering to an subject in need thereof an effective amount of a polypeptide with a sequence selected from the sequences SEQ ID Nos. 1 to 9 in which the cysteine residues are linked by disulphide bonds in the configuration I-III, II-V and IV-VI when the cysteines are numbered from the N-terminal end.
39 . Any novel feature or combination of features described herein.Join the waitlist — get patent alerts
Track US2003187187A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.